AnaptysBio, Inc.
10770 Wateridge Circle
Suite 210
San Diego
California
92121
United States
Tel: 858-362-6295
Fax: 858-362-6296
Website: http://www.anaptysbio.com/
Email: info@anaptysbio.com
About AnaptysBio, Inc.
AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, our PD-1 agonist program in a Phase 2 trial for the treatment of moderate-to-severe rheumatoid arthritis; and ANB032, our BTLA agonist program, currently in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis. Our preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody for the treatment of autoimmune and inflammatory diseases. In addition, AnaptysBio has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready. AnaptysBio has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immune-oncology, including an anti-PD-1 antagonist antibody (Jemperli (dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386).
Our corporate vision is to transform patient health by delivering innovative immunology therapeutics. Find out more about us by following us on Twitter.
CONNECT
146 articles about AnaptysBio, Inc.
-
Top 5 Companies Hiring in San Diego
4/11/2024
Looking for a biopharma job in San Diego? Check out these top five companies hiring life sciences professionals like you. -
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/11/2024
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2023 and provided a business update.
-
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
2/29/2024
AnaptysBio, Inc. today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference.
-
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
1/31/2024
AnaptysBio, Inc. today announced that Daniel Faga, president and chief executive officer, will present at Guggenheim’s 6th Annual Biotechnology Conference.
-
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
11/27/2023
AnaptysBio, Inc. (Nasdaq: ANAB) today announced an exclusive license agreement for Centessa Pharmaceuticals’ (NASDAQ: CNTA) blood dendritic cell antigen 2 (BDCA2) modulator antibody portfolio, including lead asset CBS004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases.
-
Anaptys Named a BioSpace 2024 Best Places to Work Winner
11/7/2023
AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced that, for the second year in a row, it has been named a BioSpace 2024 Best Place to Work in the small employer category.
-
Novel Immune Modulator Has Potential to Change Treatment Approach in Rheumatoid Arthritis and Ulc...
11/3/2023
A first-in-class clinical trial will initiate this quarter to determine if a checkpoint agonist can down-regulate activated T cells to help reduce inflammation and tissue damage in patients with moderate-to-severe ulcerative colitis (UC). -
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
11/2/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the third quarter ended September 30, 2023 and provided a business update.
-
Anaptys Announces Participation in November 2023 Investor Conferences
11/1/2023
AnaptysBio, Inc. announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team are scheduled to participate in multiple upcoming investor conferences in November:
-
The company’s experimental lgG4 antibody met the primary endpoint in a late-stage study of the rare skin disease. AnaptysBio will submit an application to the FDA by the third quarter of 2024.
-
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
10/11/2023
AnaptysBio, Inc. today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023.
-
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
10/9/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25.
-
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
10/9/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global Phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares.
-
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
9/18/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors.
-
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
9/12/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer, will present at the Stifel 2023 Immunology and Inflammation Virtual Summit later this month.
-
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
8/7/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.
-
AnaptysBio Announces Participation in Upcoming June 2023 Investor Conferences
5/30/2023
AnaptysBio, Inc. announced that Daniel Faga, interim president and chief executive officer of AnaptysBio, and other members of its senior management team are scheduled to participate in both of the upcoming investor conferences below:
-
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
5/11/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the first quarter ended March 31, 2023 and provided pipeline updates.
-
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
5/2/2023
AnaptysBio, Inc. (Nasdaq: ANAB) today announced the publication of data from the open-label, single-arm Phase 2 GALLOP study evaluating the efficacy, tolerability and safety of imsidolimab, its investigational anti-interleukin-36 receptor (IL-36R) IgG4 antibody for the treatment of generalized pustular psoriasis (GPP), in the British Journal of Dermatology.
-
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
4/6/2023
AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced the appointment of Rita Jain, M.D., to the company’s Board of Directors, effective immediately.